New prospects for the treatment and prevention of hepatitis C in children

Current Opinion in Pediatrics

Volumn 28, Issue 1, 2016, Pages 93-100

  Ohmer, Samantha ^a   Honegger, Jonathan ^b  

^a Biomedical Sciences Graduate Program   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

direct acting antiviral; hepatitis C virus; pediatrics; therapy; vertical transmission

Indexed keywords

ANTIVIRUS AGENT; BOCEPREVIR; DACLATASVIR; DASABUVIR; DIRECT ACTING ANTIVIRAL AGENT; HEPACIVIRIN; HEPACIVIRIN INHIBITOR; HEPATITIS VACCINE; LEDIPASVIR; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5A INHIBITOR; NONSTRUCTURAL PROTEIN 5B; OMBITASVIR; PARITAPREVIR; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2B; PROTEINASE; RIBAVIRIN; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; UNCLASSIFIED DRUG; CARRIER PROTEIN; NS-5 PROTEIN, HEPATITIS C VIRUS; NS3 PROTEIN, HEPATITIS C VIRUS; NS4A COFACTOR PEPTIDE, HEPATITIS C VIRUS; PROTEINASE INHIBITOR; VIRAL PROTEIN;

CHILDHOOD DISEASE; CLINICAL ASSESSMENT; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG EFFICACY; DRUG USE; DRUG UTILIZATION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION PREVENTION; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; VIROLOGY; VIRUS ASSEMBLY; VIRUS REPLICATION; VIRUS TRANSMISSION; ANTAGONISTS AND INHIBITORS; CHILD; COMBINATION DRUG THERAPY; PREVENTION AND CONTROL; TRANSMISSION; VERTICAL TRANSMISSION;

ANTIVIRAL AGENTS; CARRIER PROTEINS; CHILD; DRUG THERAPY, COMBINATION; HEPATITIS C; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PROTEASE INHIBITORS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84954027664     PISSN: 10408703     EISSN: 1531698X     Source Type: Journal    
DOI: 10.1097/MOP.0000000000000313     Document Type: Review

References (54)

1. Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014.
2. Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015; 61:77-87.
3. Mack CL, Gonzalez-Peralta RP, Gupta N, et al. NASPGHAN practice guidelines: diagnosis and management of hepatitis C infection in infants, children, and adolescents. J Pediatr Gastroenterol Nutr 2012; 54:838-855.
4. European Paediatric Hepatitis C Virus Network. Three broad modalities in the natural history of vertically acquired hepatitis C virus infection. Clin Infect Dis 2005; 41:45-51.
5. Garazzino S, Calitri C, Versace A, et al. Natural history of vertically acquired HCV infection and associated autoimmune phenomena. Eur J Pediatr 2014; 173:1025-1031.
6. Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol 2014; 61 (1 Suppl):S58-68.
7. Jhaveri R, Swamy GK. Hepatitis C virus in pregnancy and early childhood: current understanding and knowledge deficits. J Pediatric Infect Dis Soc 2014; 3 (Suppl 1):S13-S18.
8. Guido M, Bortolotti F, Leandro G, et al. Fibrosis in chronic hepatitis C acquired in infancy: is it only a matter of time Am J Gastroenterol 2003; 98:660-663.
9. Murray KF, Finn LS, Taylor SL, et al. Liver histology and alanine aminotransferase levels in children and adults with chronic hepatitis C infection. J Pediatr Gastroenterol Nutr 2005; 41:634-638.
10. Mohan P, Colvin C, Glymph C, et al. Clinical spectrum and histopathologic features of chronic hepatitis C infection in children. J Pediatr 2007; 150:168-174; 174 e1.
11. Henderson WA, Shankar R, Feld JJ, Hadigan CM, et al. Symptomatic and pathophysiologic predictors of hepatitis C virus progression in pediatric patients. Pediatr Infect Dis J 2009; 28:724-727.
12. Delgad-Borrego A, Smith L, Jonas MM, et al. Expected and actual case ascertainment and treatment rates for children infected with hepatitis C in Florida and the United States: epidemiologic evidence from statewide and nationwide surveys. J Pediatr 2012; 161:915-921.
13. Wirth S. Current treatment options and response rates in children with chronic hepatitis C. World J Gastroenterol 2012; 18:99-104.
14. El Sherbini A, Mostafa S, Ali E. Systematic review with meta-analysis: comparison between therapeutic regimens for paediatric chronic hepatitis C. Aliment Pharmacol Ther 2015; 42:12-19.
15. Baker RD, Baker SS. Hepatitis C in children in times of change. Curr Opin Pediatr 2015; 27:614-618.
16. Lohmann V, Korner F, Koch J, et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285:110-113.
17. Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudoparticles containing functional E1-E2 envelope protein complexes. J Exp Med 2003; 197:633-642.
18. Wakita T, Pietschmann T, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nature medicine 2005; 11:791-796.
19. Pawlotsky JM, Feld JJ, Zeuzem S, Hoofnagle JH, et al. From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol 2015; 62 (1 Suppl):S87-99.
20. Scheel TK, Rice CM. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med 2013; 19:837-849.
21. Pawlotsky JM. What are the pros and cons of the use of host-targeted agents against hepatitis C Antiviral Res 2014; 105:22-25.
22. Rowe IA, Tully DC, Armstrong MJ, et al. Effect of scavenger receptor BI antagonist ITX5061 in patients with hepatitis C virus infection undergoing liver transplantation. Liver Transpl 2015.
23. Schmidt WN, Nelson DR, Pawlotsky JM, et al. Direct-acting antiviral agents and the path to interferon independence. Clin Gastroenterol Hepatol 2014; 12:728-737.
24. Welsch C, Haselow K, Gouttenoire J, et al. Hepatitis C virus variants resistant to macrocyclic NS3-4A inhibitors subvert IFN-beta induction by efficient MAVS cleavage. J Hepatol 2015; 62:779-784.
25. Horner SM, Gale M Jr. Regulation of hepatic innate immunity by hepatitis C virus. Nat Med 2013; 19:879-888.
26. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195-1206.
27. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-2416.
28. De Luca A, Bianco C, Rossetti B. Treatment of HCV infection with the novel NS3/4A protease inhibitors. Curr Opin Pharmacol 2014; 18:9-17.
29. Kieffer TL, George S. Resistance to hepatitis C virus protease inhibitors. Curr Opin Virol 2014; 8:16-21.
30. Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol 2015.
31. Eltahla AA, Luciani F, White PA, et al. Inhibitors of the hepatitis C virus polymerase; mode of action and resistance. Viruses 2015; 7:5206-5224.
32. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370:1993-2001.
33. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in nonresponders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014; 384:1756-1765.
34. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370:1889-1898.
35. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370:1483-1493.
36. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014; 370:1983-1992.
37. Foster GR, Pianko S, Brown A, et al. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology 2015.
38. Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015; 61:1127-1135.
39. Prasad MR, Honegger JR. Hepatitis C virus in pregnancy. Am J Perinatol 2013; 30:149-159.
40. Selvapatt N, Ward T, Bailey H, et al. Is antenatal screening for hepatitis C virus cost-effective A decade's experience at a London centre. J Hepatol 2015; 63:797-804.
41. Abughali N, Maxwell JR, Kamath AS, et al. Interventions using electronic medical records improve follow up of infants born to hepatitis C virus infected mothers. Pediatr Infect Dis J 2014; 33:376-380.
42. Cottrell EB, Chou R, Wasson N, et al. Reducing risk for mother-to-infant transmission of hepatitis C virus: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2012.
43. Suryaprasad AG, White JZ, Xu F, et al. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States. Clin Infect Dis 2014; 59:1411-1419.
44. Thursz M, Fontanet A. HCV transmission in industrialized countries and resource-constrained areas. Nat Rev Gastroenterol Hepatol 2014; 11: 28-35.
45. Martin NK, Vickerman P, Grebely J, et al. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 2013; 58:1598-1609.
46. Cox AL. MEDICINE. Global control of hepatitis C virus. Science 2015; 349:790-791.
47. Roberts SS, Miller RK, Jones JK, et al. The ribavirin pregnancy registry: findings after 5 years of enrollment. Birth Defects Res A Clin Mol Teratol 2010; 88:551-559.
48. Benova L, Mohamoud YA, Calvert C, Abu-Raddad LJ, et al. Vertical transmission of hepatitis C virus: systematic review and meta-analysis. Clin Infect Dis 2014; 59:765-773.
49. Indolfi G, Azzari C, Resti M. Perinatal transmission of hepatitis C virus. J Pediatr 2013; 163:1549-1552; e1.
50. Checa Cabot CA, Stoszek SK, Quarleri J, et al. Mother-to-Child Transmission of Hepatitis C Virus (HCV) Among HIV/HCV-Coinfected Women. J Pediatr Infect Dis Soc 2013; 2:126-135.
51. European Paediatric Hepatitis C Virus Network. A significant sex-but not elective cesarean section-effect on mother-to-child transmission of hepatitis C virus infection. J Infect Dis 2005; 192:1872-1879.
52. Swadling L, Capone S, Antrobus RD, et al. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Sci Transl Med 2014; 6:153ra261.
53. Honegger JR, Zhou Y, Walker CM. Will there be a vaccine to prevent HCV infection Semin Liver Dis 2014; 34:79-88.
54. Mok J, Pembrey L, Tovo PA, et al. When does mother to child transmission of hepatitis C virus occur Arch Dis Child Fetal Neonatal Ed 2005; 90:F156-F160.